Target intelligence / Profile preview

CD3 antigen (T cell co-receptor) (CD3)

Target
CD3
Molecular classification
Receptor, Co-receptor, Immunoglobulin superfamily, Transmembrane signaling protein
01

Overview

The **CD3 antigen** is a multimeric protein complex and a definitive surface marker of **T cells**, where it functions as a key component of the T cell receptor (TCR) complex[1][3][7]. It consists of four main subunits: CD3γ, CD3δ, CD3ε, and CD3ζ, assembled as three dimers (γε, δε, ζζ), each with transmembrane and cytoplasmic domains containing immunoreceptor tyrosine-based activation motifs (ITAMs)[1][3][5][7]. CD3 associates non-covalently with the TCR and mediates signal transduction upon antigen recognition, leading to T cell activation, proliferation, differentiation, and effector function[1][2][3][7]. Because of its central role in T cell biology, **CD3 is a major therapeutic target** in immunology—for example, by using anti-CD3 antibodies to either activate or suppress the immune response in settings including transplantation, autoimmunity, and cancer immunotherapy[2][6][7]. CD3 is broadly expressed on all mature T cells, making it a standard marker for T cell identification and quantification in research and clinical diagnostics[5][7]. Notable clinical risks of therapeutics targeting CD3 include cytokine release syndrome and increased susceptibility to infection due to immunosuppression[2][7].

Other names
Cluster of Differentiation 3T3 antigenCD3 complexT cell co-receptor
02

Mechanism of action

TCR signaling modulation, Immune modulation via T cell activation or depletion, Induction of T cell apoptosis (in some therapeutic contexts), Immune synapse formation

03

Biological functions

Immune responseSignal transductionT cell activationAntigen recognition
04

Disease associations

CancerInfectionAutoimmune diseaseInflammationOther (immune-related disorders)
05

Safety considerations

Cytokine release syndromeImmunosuppression/infection riskOpportunistic infectionsInfusion reactionsAutoimmunity
06

Interacting drugs

Muromonab-CD3 (OKT3)

4 more in the full profile.

07

Biomarkers

CD3 expression for T cell identificationMinimal residual disease monitoring in leukemia/lymphomaImmunophenotyping for lymphoma subtyping

Beyond the preview

Go deeper on CD3 antigen (T cell co-receptor) (CD3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD3 antigen (T cell co-receptor) (CD3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call